

# Min-Hee Ryu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2889705/publications.pdf>

Version: 2024-02-01

140  
papers

5,922  
citations

147801

31  
h-index

85541

71  
g-index

145  
all docs

145  
docs citations

145  
times ranked

6439  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic value of natural killer cell activity for patients with HER2+ advanced gastric cancer treated with first-line fluoropyrimidine+ platinum doublet plus trastuzumab. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 829-838.	4.2	7
2	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	5.3	9
3	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. <i>Gastric Cancer</i> , 2022, 25, 197-206.	5.3	72
4	Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study. <i>Gastric Cancer</i> , 2022, 25, 170-179.	5.3	6
5	Insertion+deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab. <i>Gastric Cancer</i> , 2022, 25, 226-234.	5.3	8
6	Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). <i>Gastric Cancer</i> , 2022, 25, 609-618.	5.3	3
7	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2022, 23, 234-247.	10.7	268
8	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2+ positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).. <i>Journal of Clinical Oncology</i> , 2022, 40, 242-242.	1.6	5
9	Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 322-322.	1.6	3
10	Regorafenib plus nivolumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Multicenter phase 2 trial (RENOBATE).. <i>Journal of Clinical Oncology</i> , 2022, 40, 415-415.	1.6	3
11	Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation: A retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 410-410.	1.6	0
12	Predictive biomarkers for the efficacy of nivolumab as 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial. <i>BMC Cancer</i> , 2022, 22, 378.	2.6	16
13	Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis. <i>Cancer Research and Treatment</i> , 2022, 54, 1167-1174.	3.0	8
14	Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab. <i>Gastric Cancer</i> , 2022, 25, 794-803.	5.3	7
15	Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210979.	3.2	7
16	Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11539-11539.	1.6	0
17	Abstract 2140: Association between gene expression signatures and outcomes of pembrolizumab (pembro) and paclitaxel (pac) in advanced gastric cancer (GC): Exploratory analysis from KEYNOTE-061. <i>Cancer Research</i> , 2022, 82, 2140-2140.	0.9	0
18	A randomized phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11538-11538.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group (KCSC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e18759-e18759.	1.6	0
20	Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). <i>Gastric Cancer</i> , 2021, 24, 156-167.	5.3	29
21	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. <i>Journal of Clinical Oncology</i> , 2021, 39, 966-977.	1.6	122
22	Expression of the immune checkpoint molecule V-set immunoglobulin domain-containing 4 is associated with poor prognosis in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 327-340.	5.3	13
23	Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. <i>Liver Cancer</i> , 2021, 10, 107-114.	7.7	66
24	Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSC-ST19-16). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110428.	3.2	6
25	Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellularâ€“cholangiocarcinoma. <i>Liver International</i> , 2021, 41, 1398-1408.	3.9	22
26	Sequential Treatment of Sorafenibâ€“Regorafenib Versus Sorafenibâ€“Physicianâ€™s Choice: A Propensity Score-Matched Analysis. <i>Targeted Oncology</i> , 2021, 16, 401-410.	3.6	5
27	Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3665-3671.	2.5	12
28	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958.	5.3	61
29	Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2â€“Targeted Agent in the Real-World Setting. <i>Cancer Research and Treatment</i> , 2021, 53, 436-444.	3.0	4
30	Role of palliative radiotherapy in bleeding control in patients with unresectable advanced gastric cancer. <i>BMC Cancer</i> , 2021, 21, 413.	2.6	14
31	Kinetics of the neutrophilâ€“lymphocyte ratio during PDâ€“1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 2189-2199.	3.9	26
32	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib. <i>Hepatology Research</i> , 2021, 51, 796-802.	3.4	4
33	Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSC-ST19-16).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4056-4056.	1.6	1
34	Comparison of PD-L1 immunohistochemical assays in advanced gastric adenocarcinomas using endoscopic biopsy and paired resected specimens. <i>Pathology</i> , 2021, 53, 586-594.	0.6	10
35	PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2903-2913.	1.6	154
36	Reply to D.-C. Mo et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 3884-3886.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational, multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 272-272.	1.6	4
38	520â€Preliminary biomarker and pharmacodynamic (PD) activity of the TGFÎ² inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with advanced solid tumors. , 2021, 9, A550-A550.		2
39	New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy. <i>World Journal of Gastroenterology</i> , 2021, 27, 8357-8369.	3.3	0
40	Prospective multicentre randomised clinical trial comparing survival rates, quality of life and nutritional status between advanced gastric cancer patients with different follow-up intensities: study protocol for the STOFOLUP trial. <i>BMJ Open</i> , 2021, 11, e056187.	1.9	3
41	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153.	5.3	45
42	How Cancer Patients Perceive Clinical Trials (CTs) in the Era of CTs: Current Perception and Its Differences Between Common and Rare Cancers. <i>Journal of Cancer Education</i> , 2020, 35, 545-556.	1.3	1
43	Impact of l-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor. <i>Investigational New Drugs</i> , 2020, 38, 493-499.	2.6	4
44	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519.	5.3	155
45	S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1045-1056.	10.7	39
46	Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study. <i>Oncologist</i> , 2020, 25, e1785-e1793.	3.7	4
47	Effectiveness and Safety of Nivolumab in Childâ€Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study. <i>Cancers</i> , 2020, 12, 1968.	3.7	40
48	The role of novel fusion genes in human GIST cell lines derived from imatinib-resistant GIST patients: A therapeutic potential of fusion gene. <i>Biochemical and Biophysical Research Communications</i> , 2020, 529, 699-706.	2.1	9
49	Establishment of patient-derived xenografts from patients with gastrointestinal stromal tumors: analysis of clinicopathological characteristics related to engraftment success. <i>Scientific Reports</i> , 2020, 10, 7996.	3.3	4
50	Pembrolizumab versus paclitaxel for previously treated patients with PD-L1â€positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4503-4503.	1.6	31
51	The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4512-4512.	1.6	26
52	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4513-4513.	1.6	7
53	The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4537-4537.	1.6	38
54	Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2â€ advanced gastric or gastroesophageal junction cancer (GC/GEJC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 278-278.	1.6	39

#	ARTICLE	IF	CITATIONS
55	Clinical implications of neutrophil-to-lymphocyte ratio and MDSC kinetics in gastric cancer patients treated with ramucirumab plus paclitaxel. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 621-630.	2.2	7
56	Prognostic role of mismatch repair deficiency (MMR-D) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy for metastatic and locally advanced unresectable gastric cancers (GCs).. Journal of Clinical Oncology, 2020, 38, 4566-4566.	1.6	1
57	Diagnostic accuracy of CT-staging of advanced gastric cancer following neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2020, 38, 4551-4551.	1.6	0
58	Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses. Oncologist, 2019, 24, e1443-e1449.	3.7	4
59	Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours. British Journal of Cancer, 2019, 121, 819-826.	6.4	2
60	Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience. Cancer Medicine, 2019, 8, 1034-1043.	2.8	11
61	Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib. Oncologist, 2019, 24, e1212-e1218.	3.7	12
62	Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. Future Oncology, 2019, 15, 567-577.	2.4	20
63	Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer, 2019, 22, 527-535.	5.3	88
64	Predictive biomarkers for the efficacy of nivolumab as a third-line therapy in patients with advanced gastric cancer (AGC): From a subset analysis of ATTRACTION-2 phase III trial.. Journal of Clinical Oncology, 2019, 37, 152-152.	1.6	6
65	Intra-abdominal desmoid tumors mimicking gastrointestinal stromal tumors – 8 cases: A case report. World Journal of Gastroenterology, 2019, 25, 2010-2018.	3.3	3
66	Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. Gastric Cancer, 2018, 21, 802-810.	5.3	7
67	Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer, 2018, 21, 819-830.	5.3	24
68	Use of complementary and alternative medicine by lymphoma survivors in South Korea. European Journal of Oncology Nursing, 2018, 33, 91-96.	2.1	11
69	RhoGAP domain-containing fusions and PPAPDC1A fusions are recurrent and prognostic in diffuse gastric cancer. Nature Communications, 2018, 9, 4439.	12.8	21
70	A Prospective Randomized Comparison of a Covered Metallic Ureteral Stent and a Double-J Stent for Malignant Ureteral Obstruction. Korean Journal of Radiology, 2018, 19, 606.	3.4	15
71	Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treatment Reviews, 2018, 66, 104-113.	7.7	78
72	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2018, 392, 123-133.	13.7	984

#	ARTICLE	IF	CITATIONS
73	Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.. Journal of Clinical Oncology, 2018, 36, 4062-4062.	1.6	10
74	JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).. Journal of Clinical Oncology, 2018, 36, TPS195-TPS195.	1.6	12
75	Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis. Cancer Research and Treatment, 2018, 50, 518-529.	3.0	10
76	Role of resection following focal progression with standard doses of imatinib in patients with advanced gastrointestinal stromal tumor: Results of propensity score analyses.. Journal of Clinical Oncology, 2018, 36, 11532-11532.	1.6	1
77	Phase II trial of continuous dosing of regorafenib in patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs) after failure of imatinib and sunitinib.. Journal of Clinical Oncology, 2018, 36, 11537-11537.	1.6	0
78	Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer. Gastric Cancer, 2017, 20, 146-155.	5.3	11
79	Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage III&IV gastric cancer. Gastric Cancer, 2017, 20, 182-189.	5.3	6
80	A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer. Oncologist, 2017, 22, 129-e8.	3.7	18
81	Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers. Gastroenterology, 2017, 153, 536-549.e26.	1.3	90
82	Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. British Journal of Cancer, 2017, 117, 25-32.	6.4	74
83	Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis. Gastric Cancer, 2017, 20, 970-977.	5.3	13
84	A potential pitfall in evaluating HER2 immunohistochemistry for gastric signet ring cell carcinomas. Pathology, 2017, 49, 38-43.	0.6	13
85	Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Cancer Chemotherapy and Pharmacology, 2017, 79, 139-146.	2.3	28
86	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 2461-2471.	13.7	1,749
87	Comparison of efficacy and tolerance between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer: Study protocol for a randomized controlled trial. Contemporary Clinical Trials Communications, 2017, 8, 55-61.	1.1	1
88	Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. Cancer Research and Treatment, 2017, 49, 851-868.	3.0	50
89	Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients. PLOS ONE, 2017, 12, e0176045.	2.5	28
90	Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers. Oncotarget, 2017, 8, 33844-33854.	1.8	20



#	ARTICLE	IF	CITATIONS
91	Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2-2.	1.6	64
92	Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of GASTric cancer HER2 reassessment study 3 (GASTHER3).. <i>Journal of Clinical Oncology</i> , 2017, 35, 27-27.	1.6	4
93	Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors. <i>Oncotarget</i> , 2017, 8, 76712-76721.	1.8	5
94	Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. <i>Cancer Research and Treatment</i> , 2017, 49, 350-357.	3.0	23
95	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. <i>Oncotarget</i> , 2016, 7, 10547-10556.	1.8	52
96	Upregulation of brain-derived neurotrophic factor in advanced gastric cancer contributes to bone metastatic osteolysis by inducing long pentraxin 3. <i>Oncotarget</i> , 2016, 7, 55506-55517.	1.8	36
97	Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-6.	1.5	4
98	Over-the-wire versus through-the-scope stents for the palliation of malignant gastric outlet obstruction: A retrospective comparison study. <i>European Radiology</i> , 2016, 26, 4249-4258.	4.5	14
99	Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients. <i>BMC Cancer</i> , 2016, 16, 900.	2.6	67
100	Partially-covered stent placement versus surgical gastrojejunostomy for the palliation of malignant gastroduodenal obstruction secondary to pancreatic cancer. <i>Abdominal Radiology</i> , 2016, 41, 2233-2240.	2.1	14
101	Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis. <i>British Journal of Cancer</i> , 2016, 114, 1185-1190.	6.4	35
102	Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 226-233.	5.3	32
103	Gastroduodenal stent placement versus surgical gastrojejunostomy for the palliation of gastric outlet obstructions in patients with unresectable gastric cancer: a propensity score-matched analysis. <i>European Radiology</i> , 2016, 26, 2436-2445.	4.5	26
104	Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). <i>European Journal of Cancer</i> , 2016, 53, 42-50.	2.8	76
105	Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT). <i>European Journal of Cancer</i> , 2016, 52, 201-208.	2.8	8
106	Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 579-585.	5.3	11
107	Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) vs IV paclitaxel in patients with gastric cancer after failure of first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4016-4016.	1.6	3
108	Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4135-TPS4135.	1.6	6

#	ARTICLE	IF	CITATIONS
109	Clinical significance of MET amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum (FP) combination chemotherapy.. Journal of Clinical Oncology, 2016, 34, 69-69.	1.6	1
110	Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma. Oncotarget, 2016, 7, 74303-74313.	1.8	19
111	Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha Mutated Gastrointestinal Stromal Tumors. Cancer Research and Treatment, 2016, 48, 546-552.	3.0	38
112	Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications. Cancer Research and Treatment, 2016, 48, 162-170.	3.0	13
113	A multinational phase II clinical trial of neoadjuvant imatinib for large gastrointestinal stromal tumor of the stomach.. Journal of Clinical Oncology, 2016, 34, 130-130.	1.6	1
114	FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry. American Journal of Clinical Pathology, 2015, 143, 865-872.	0.7	18
115	Comparison of Chemoembolization with and without Radiation Therapy and Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis. Journal of Vascular and Interventional Radiology, 2015, 26, 320-329.e6.	0.5	75
116	Percutaneous Radiofrequency Ablation of Hepatic Metastases from Gastric Adenocarcinoma after Gastrectomy. Journal of Vascular and Interventional Radiology, 2015, 26, 1172-1179.	0.5	10
117	Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. European Journal of Cancer, 2015, 51, 482-488.	2.8	103
118	Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression. BMC Cancer, 2015, 15, 119.	2.6	23
119	Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with Imatinib. Annals of Surgical Oncology, 2015, 22, 362-369.	1.5	4
120	A randomized phase III study of neoadjuvant chemotherapy with docetaxel(D), oxaliplatin(O), and S-1(S) (DOS) followed by surgery and adjuvant S-1 vs. surgery and adjuvant S-1 for resectable advanced gastric cancer (PRODIGY).. Journal of Clinical Oncology, 2015, 33, TPS4136-TPS4136.	1.6	7
121	Efficacy and safety of regorafenib in Korean patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib: A multicenter study based on the management access program.. Journal of Clinical Oncology, 2015, 33, 175-175.	1.6	0
122	Phase II study of neoadjuvant chemotherapy with docetaxel, capecitabine, cisplatin and bevacizumab for initially unresectable gastric cancer with invasion of adjacent organs or paraaortic lymph node metastasis.. Journal of Clinical Oncology, 2015, 33, e15060-e15060.	1.6	0
123	A phase III study to compare efficacy and safety of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with metastatic or recurrent gastric cancer after failure of first-line chemotherapy (DREAM).. Journal of Clinical Oncology, 2015, 33, TPS4138-TPS4138.	1.6	0
124	Next-generation sequencing to reveal somatic mutations that confer sensitivity to everolimus.. Journal of Clinical Oncology, 2015, 33, 11010-11010.	1.6	0
125	Phase I/II study of a combination of capecitabine, cisplatin, and intraperitonealdocetaxel (XP ID) in patients with advanced gastric cancer with peritoneal metastasis.. Journal of Clinical Oncology, 2015, 33, 4026-4026.	1.6	0
126	Phase II study of everolimus as a salvage treatment after failure of fluoropyrimidine and platinum in patients with metastatic gastric cancer positive for pS6Ser240/4 expression.. Journal of Clinical Oncology, 2015, 33, 4057-4057.	1.6	0



#	ARTICLE	IF	CITATIONS
127	Prognostic significance of neuroendocrine components in gastric carcinomas. <i>European Journal of Cancer</i> , 2014, 50, 2802-2809.	2.8	52
128	A phase I dose escalation study to evaluate safety and tolerability of cabazitaxel (Cbz) as a single agent in patients (pts) with advanced gastric adenocarcinoma who have failed prior chemotherapy (CT) regimens (GASTANA).. <i>Journal of Clinical Oncology</i> , 2014, 32, 141-141.	1.6	0
129	Randomized phase III trial of imatinib (IM) rechallenge versus placebo (PL) in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): RIGHT study.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA10502-LBA10502.	1.6	5
130	A phase I dose-finding study of everolimus in combination with capecitabine and oxaliplatin (XELOX) as the first-line chemotherapy for patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 86-86.	1.6	0
131	Randomized phase III trial of imatinib (IM) rechallenge versus placebo in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): Right study.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA10502-LBA10502.	1.6	4
132	The role of surgical resection following imatinib treatment in patients with metastatic or recurrent GIST.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10550-10550.	1.6	0
133	Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?. <i>Human Pathology</i> , 2012, 43, 413-422.	2.0	67
134	A phase II study of tivantinib monotherapy in patients with previously treated advanced or recurrent gastric cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4082-4082.	1.6	10
135	Adjuvant Chemotherapy in Gastric Cancer. <i>Korean Journal of Medicine</i> , 2012, 83, 291.	0.3	1
136	The role of surgical cytoreduction before imatinib therapy in patients with advanced GIST.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10093-10093.	1.6	0
137	A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor. <i>Oncology</i> , 2009, 76, 326-332.	1.9	26
138	ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1745-1751.	2.4	14
139	Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 623-629.	2.3	65
140	Patterns of Progression in Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 17-24.	1.3	33